In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1855 News Items found
A new study suggests that healthcare providers should consider looking for monoclonal gammopathy of undetermined significance (MGUS) in younger African Americans.
Finding
Myeloma Precursor Disease Can Start Much Earlier than Expected, Especially in African Americans

New research has found that a precancerous blood condition can linger undetected for more than 20 years.
Memorial Sloan Kettering medical oncologist Paul Hamlin
Announcement
FDA Approves CAR T Cell Therapy for Non-Hodgkin Lymphoma

This is the second regulatory approval of the cell-based immunotherapy for a blood cancer.
Stem cells induced to become cardiomyocytes
In the Lab
Stem Cell Research Probes Why a Breast Cancer Treatment Sometimes Damages the Heart

Investigators are looking at how and why the breast cancer drug trastuzumab sometimes causes long-lasting and potentially serious cardiac side effects.
MSK woman
Q&A
The Benefits of a Metastatic Breast Cancer Support Group: An Interview with a Social Worker

Learn how a support group could help you if you’ve been diagnosed with metastatic breast cancer.
A micrograph image of breast cancer cells.
In the Lab
Research Reveals How Sleeping Cancer Cells Wake Up

MSK investigators are studying how dormant cancer cells can become reactivated after remaining hidden in the body for years.
Image of DNA helix with sequence in the background
In the Clinic
Genetic ‘Scars’ Provide Clues for Tailoring Cancer Treatment

For the first time, scientists have determined the extent of DNA repair deficiencies across cancer types. Learn what it means for patients.
MSK medical oncologist Jasmeet Singh
Quiz
How Much Do You Know about Breast Cancer Screening? Take Our Quiz

Take a short quiz to test your knowledge of breast cancer screening.
Memorial Sloan Kettering Is Designated as a Qualified Provider-Led Entity under the Protecting Access to Medicare Act

Memorial Sloan Kettering Cancer Center (MSK) is now recognized as the first dedicated cancer center in the United States to be designated as a qualified provider-led entity (QPLE) under Medicare’s program for appropriate use criteria (AUC). This designation allows MSK to establish best practice standards for the use of CT scans, MRI, and nuclear medicine imaging from initial screening and diagnosis through all stages of cancer care, including survivorship.
A hand holding a thin optical fiber giving off a red light.
In the Clinic
Light-Activated Drug Destroys Small Prostate Cancers with Fewer Side Effects

A novel treatment for prostate cancer involves a light-sensitive drug that destroys small tumors and the blood vessels that feed them.
m6A Enzymes Found to Be Central to the Development of AML

A team of researchers from Memorial Sloan Kettering Cancer Center (MSK) and Weill-Cornell Medical College have identified, for the first time, a new molecular pathway that is required for acute myeloid leukemia (AML) development. This work could provide a rationale for targeting the RNA methylation program in myeloid leukemia.